Week In Review: ImmuneOnco Out-Licenses Two Antibodies In $2 Billion Deal
August 03, 2024 at 15:00 PM EDT
Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million, and up to more than $2 billion in milestones.
